Pink Sheets: LifeCycle Pharma A/S (LFCYF) news stock charts
LifeCycle Pharma A/S (LFCYF/LFCYF.PK) Penny Investment Summary:
LifeCycle Pharma A/S operates as a specialty pharmaceutical company. The company develops a product portfolio, which includes products for immunosuppression and organ transplantation, as well as products to combat certain cardiovascular diseases. The company offers LCP-FenoChol for the treatment of dyslipidemia as an adjunct to diet in adult patients under the brand name Fenoglide. Its product programs include LCP-Tacro, a Phase III product formulation of tacrolimus for immunosuppression treatment in kidney and liver transplant recipients; LCP-Tacro, a Phase II clinical trial product for the treatment of autoimmune hepatitis; LCP-AtorFen, which has completed Phase II studies for the treatment of dyslipidemia; LCP-Feno, a Phase I clinical trial product for the treatment of dyslipidemia; LCP-Siro, a Phase I clinical trial product for organ transplant/autoimmune diseases; and LCP-3301, a pre-clinical product for transplant/autoimmune diseases. LifeCycle Pharma has strategic alliances with Sciele Pharma, Inc. to market Fenoglide in the United States, Canada, and Mexico; Sandoz, Inc. to develop, manufacture, and commercialize LCP-Feno as an AB-rated generic version of Tricor for the United States market; and Mylan, Inc. to develop, manufacture, and commercialize LCP-Feno as a generic version of Lipanthyl for the European market. The company is based in Horsholm, Denmark with an additional office in New York.LIFECYCLE PHARMA AS (LFCYF:Pink OTC Markets Inc)
Snapshot of LIFECYCLE PHARMA AS (LFCYF)
|
OPEN
$0.98
|
PREVIOUS CLOSE
$0.98
|
|
|
DAY HIGH
$0.98
|
DAY LOW
$0.98
|
|
|
52 WEEK HIGH
05/27/09 - $2.30
|
52 WEEK LOW
12/11/09 - $0.96
|
|
|
MARKET CAP
--
|
AVERAGE VOLUME 10 D
50.0
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
0.0
|
|
|
LFCYF Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for LIFECYCLE PHARMA AS (LFCYF)
LifeCycle Pharma A/S announced earnings results for the fourth quarter and full year ended December 31, 2009. For the year, the company reported operating loss of DKK 279.53 million, net loss of DKK 271 million or DKK 4.80 basic and diluted loss per share on the revenue of DKK 2.48 million compared to operating loss of DKK 174.06 million, net loss of DKK 149.8 million or DKK 3.06 basic and diluted loss per share on the revenue of DKK 170.12 million for the same period last year. The company reported cash flow used in operating activities of DKK 251.16 million compared to DKK 102.56 million for the same period last year. For the quarter, the company reported operating loss of DKK 60.27 million, net loss of DKK 59.75 million or DKK 1.06 basic and diluted loss per share on the revenue of DKK 182 million compared to operating loss of DKK 92.16 million, net loss of DKK 80.65 million or DKK 1.43 basic and diluted loss per share on the revenue of DKK 4.81 million for the same period last year. The company reported cash flow used in operating activities of DKK 56.8 million compared to DKK 68.62 million for the same period last year. For the fiscal 2010, the company is projecting an operating loss of DKK 260-290 million compared to the realized operating loss of DKK 279.5 million in 2009. The net loss is likewise expected to be in the range of DKK 260-290 million compared to the net loss of DKK 271.0 million in 2009. The group's December 31, 2010 cash position is expected to be in the range of DKK 50-100 million. These estimates are subject to possible changes primarily due to the timing and variation of clinical activities, related costs, royalty and other partner income, and fluctuating currency exchange rates. The company announced Dr. William Polvino was appointed as President and Chief Executive Officer.
LifeCycle Pharma A/S, Board Meeting, Feb 24, 2010 Agenda: To issue 588,000 warrants to employees of the company and the company's subsidiary.
LifeCycle Pharma A/S, 2009 Earnings Call, Feb-25-2010
LifeCycle Pharma A/S financial resources
LFCYF Competitors
| Company | Last | Change | |
| No competitor information is available for LFCYF. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | LFCYF | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
LFCYF |
||
LFCYF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Pink Sheets: More Recent Financial News About LifeCycle Pharma A/S
Q3 2009 LifeCycle Pharma, Inc Earnings Release - Time Not Supplied
Read article